InsidersTradesSigma
Total declarations
Companies
▲ Purchases (9 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
9
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-52.8%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Ehrlich Christopher B, Chief Executive Officer. Insider active across 3 companies, notably eFFECTOR Therapeutics, Inc.. Aggregated, 15 reports have been recorded. Breakdown: 9 buys · 0 sell. Total volume traded: €120k. History available since 25 August 2021. The latest transaction was filed on 4 October 2022 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations15 total
5,312,983 sharesCommon StockSEC:0001213900-24-084830:0
1,125,000 sharesCommon StockSEC:0001213900-24-015026:0
346 shares@ US$0.570.2% of flowCommon StockSEC:0001209191-22-052933:0
Ideal exit: 1 Jul 2023 (T+270)
18,867 shares@ US$0.559.0% of flowCommon StockSEC:0001209191-22-051313:0
Ideal exit: 23 Jun 2023 (T+270)
2,000 shares@ US$4.457.2% of flowCommon StockSEC:0001209191-22-011731:0
Ideal exit: 11 Nov 2022 (T+270)
1,000 shares@ US$4.923.6% of flowCommon StockSEC:0001209191-22-008529
Ideal exit: 5 Nov 2022 (T+270)
1,000 shares@ US$4.923.9% of flowCommon StockSEC:0001209191-22-008529:0
Ideal exit: 5 Nov 2022 (T+270)
5,000 shares@ US$5.1520.9% of flowCommon StockSEC:0001209191-22-007349:0
Ideal exit: 31 Oct 2022 (T+270)
5,000 shares@ US$5.1519.0% of flowCommon StockSEC:0001209191-22-007349
Ideal exit: 31 Oct 2022 (T+270)
5,000 shares@ US$5.30321.6% of flowCommon StockSEC:0001209191-22-005721:0
Ideal exit: 24 Oct 2022 (T+270)
5,000 shares@ US$5.30319.6% of flowCommon StockSEC:0001209191-22-005721
Ideal exit: 24 Oct 2022 (T+270)
36,733 shares@ US$10.0050.0% of flowClass A common stockSEC:0000899243-21-039941:0
36,733 shares@ US$10.0050.0% of flowClass A common stockSEC:0000899243-21-039941
142,168 shares0Common StockSEC:0001209191-21-053731:0
142,168 shares0Common StockSEC:0001209191-21-053731
15 of 15 declarations
About Ehrlich Christopher B
Christopher B. Ehrlich is the Chief Executive Officer and Secretary of eFFECTOR Therapeutics, Inc. and PHOENIX BIOTECH ACQUISITION CORP. In his roles, he oversees the daily operations and overall strategy of the companies, focusing on innovation in the biotechnology field. His leadership is essential to achieving the growth and development objectives of the firms.
